FDA approves Lilly's Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areata
RegulatoryapprovedOlumiantPositive
AI Analysis
Summary
FDA approved Lilly's Olumiant (baricitinib) for pediatric patients aged 12 and older with severe alopecia areata, based on positive Phase 3 BRAVE-AA-PEDS trial data demonstrating substantial scalp hair regrowth.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
FDA approval for pediatric patients 12 years of age and older with severe alopecia areata, supported by Phase 3 BRAVE-AA-PEDS data showing substantial scalp hair regrowth and improvements in eyebrows
Importance:8/10
Sentiment:
0.90
FDA approvalpediatricalopecia areataPhase 3dermatology
Related Companies
Read the original article
Published by PR Newswire Pharma on September 25, 2026 9:11 PM